Core Viewpoint - The company has successfully administered the first dose of its self-developed radiolabeled drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research Focus - The study specifically targets patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The research will systematically evaluate the core clinical value of 3D1015, focusing on the drug's safety and radiation dosimetry assessment [1] - The study aims to collect in-depth pharmacokinetic characteristics and dose exploration data of the drug in humans, providing direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

Core Viewpoint - The company has successfully administered its first self-developed radiopharmaceutical drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research - The study focuses on evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive mCRPC [1] - The research aims to systematically assess the core clinical value of 3D1015, emphasizing drug safety and dosimetry evaluation [1] - The study will collect in-depth pharmacokinetic characteristics and dose exploration data to provide direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

Core Insights - The company announced a significant breakthrough in the development of GPN02006, a global innovative radiolabeled drug conjugate (RDC) for diagnosing hepatocellular carcinoma (HCC) [1] - The clinical results of the investigator-initiated trial (IIT) were publicly presented at the Chengdu 2025 Future XDC New Drug Conference, marking a milestone in the company's oncology nuclear drug development efforts [1] - GPN02006 is expected to become the world's first RDC product targeting the GPC-3 marker for HCC diagnosis [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號：00512) 自願性公告 董事會欣然公告，本集團與武漢睿迪輻生物科技有限公司、傑科（天津）生物醫藥有 限公司合作開發的用於診斷肝細胞癌（hepatocellular carcinoma，HCC）的全球創新 放射性核素偶聯藥物「( RDC」) GPN02006 在中國開展的研究者發起的臨床研究（IIT 臨床研究），近日取得了里程碑式突破，並於成都 2025 未來 XDC 新藥大會中公開 發表了臨床結果。該研究是一項前瞻性、單中心、診斷性的臨床研究，在超過 80 例 臨床懷疑或者確診的 HCC 患者中，使用 GPN02006 並進行正電子發射斷層成像/電 腦斷層掃描（PET/CT）或正電子發射斷層成像/磁共振成像（PET/MRI）顯像，以初 步評估該產品對 HCC 的診 ...